Literature DB >> 27082510

We Underdose Antibiotics in Patients on CRRT.

Alexander R Shaw1, Weerachai Chaijamorn1,2, Bruce A Mueller1.   

Abstract

Appropriate antibiotic dosing in critically ill, infected, patients receiving continuous renal replacement therapy (CRRT) is crucial to improve patient outcomes. Severe sepsis and septic shock result in changes in pharmacokinetic parameters, including increased volume of distribution, hypoalbuminemia, and changes in renal and nonrenal clearances. The lack of CRRT standardization, nonrecognition of how CRRT variability affects antibiotic removal, fear of antibiotic toxicity, and limited drug dosing resources all contribute to suboptimal antibiotic therapy. Even when antibiotic CRRT pharmacokinetic studies are available, they are often based on old CRRT methodologies that do not exist in contemporary CRRT practice, resulting in unhelpful/inaccurate dosing recommendations. Application of these older doses in Monte Carlo simulation studies reveals that many of the recommended dosing regimens will never attain pharmacodynamic targets. In this review, using cefepime as an example, we illustrate whether clinicians are likely to achieve pharmacokinetic/pharmacodynamic targets when the recommended dosing regimens are prescribed in this patient population. We encourage clinicians to aggressively dose antibiotics with large loading dose and higher maintenance doses to reach the targets.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27082510     DOI: 10.1111/sdi.12496

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  8 in total

Review 1.  Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment.

Authors:  Sadudee Peerapornratana; Carlos L Manrique-Caballero; Hernando Gómez; John A Kellum
Journal:  Kidney Int       Date:  2019-06-07       Impact factor: 10.612

2.  Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial.

Authors:  Ilona Nowak-Kózka; Kamil J Polok; Jacek Górka; Jakub Fronczek; Anna Gielicz; Bożena Seczyńska; Mirosław Czuczwar; Bartosz Kudliński; Wojciech Szczeklik
Journal:  Pharmacol Rep       Date:  2020-01-04       Impact factor: 3.024

3.  Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.

Authors:  Leigh Anne Keough; Amy Krauss; Joanna Q Hudson
Journal:  Int J Clin Pharm       Date:  2018-07-26

4.  Beta-lactam dosing during continuous renal replacement therapy: a survey of practices in french intensive care units.

Authors:  Elodie Matusik; Justine Lemtiri; Guillaume Wabont; Fabien Lambiotte
Journal:  BMC Nephrol       Date:  2022-01-29       Impact factor: 2.388

5.  Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.

Authors:  Stephan Braune; Christina König; Jason A Roberts; Axel Nierhaus; Oliver Steinmetz; Michael Baehr; Stefan Kluge; Claudia Langebrake
Journal:  Crit Care       Date:  2018-01-30       Impact factor: 9.097

6.  Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.

Authors:  Weerachai Chaijamorn; Taniya Charoensareerat; Nattachai Srisawat; Sutthiporn Pattharachayakul; Apinya Boonpeng
Journal:  J Intensive Care       Date:  2018-09-12

Review 7.  The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review.

Authors:  Alessandro Lazzaro; Gabriella De Girolamo; Valeria Filippi; Giuseppe Pietro Innocenti; Letizia Santinelli; Giancarlo Ceccarelli; Enrico Maria Trecarichi; Carlo Torti; Claudio Maria Mastroianni; Gabriella d'Ettorre; Alessandro Russo
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

8.  The landscape of renal replacement therapy in Veterans Affairs Medical Center intensive care units.

Authors:  Chandan Vangala; Maulin Shah; Natasha N Dave; Layth Al Attar; Sankar D Navaneethan; Venkat Ramanathan; Susan Crowley; Wolfgang C Winkelmayer
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.